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ABSTRACT 
Objective: To develop rapid, accurate, reproducible, validated and economical difference spectroscopy method for the simultaneous determination 
of moxifloxacin (MFN) and cefixime (CEF) in tablet dosage forms. 
Methods: The method comprised the measurement of the absorbance of a solution of the tablet extract in 0.1 M NaOH relative to that of an 
equimolar solution in 0.1 M HC1 at 254 nm for MFN and 292 nm for CEF. The presence of identical isosbestic points for pure drug solutions and 
tablet extracts indicated the non-interference of excipients in the absorption at these wavelengths. 
Results: The method was found to be linear over the concentration range of 10-50 μg/ml for CEF and 4-20 μg/ml for MFN. Accuracy was found to 
be in the range of 99.91-101.18%. Relative standard deviation for precision and intermediate precision was found to be less than 2%. The 
developed method was successfully applied for the simultaneous estimation of Moxifloxacin and Cefixime in tablet formulation. The results obtained 
from the validation experiments prove that the developed method is suitable for routine analysis. 
Conclusion: This method is simple, selective, linear, precise, and accurate and sensitive hence can be successfully employed for the routine quality 
control of dosage forms containing both the drugs in pharmaceutical industries. 
Keywords: Moxifloxacin, Cefixime, Difference Spectrophotometry, Method validation. 
 
INTRODUCTION 
Cefixime Trihydrate [(6R,7R)-7-(2-(2-Amino-4-thiazolyl) glyoxyl-
amido]-8-oxo-3-vinyl-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carbo-
xylic acid, 72-(Z)-[O-(carboxymethyl) oxime] trihydrate [fig. 1(a)] is 
semi synthetic, oral, third-generation cephalosporin antibiotic like 
ceftriaxone and cefotaxime [1]. It acts by inhibition of muco peptide 
synthesis in the bacterial cell wall [2]. 
Cefixime is active against a very wide spectrum of bacteria and is 
used in the treatment of otitis media, respiratory tract infection, and 
typhoid fever, complicated and uncomplicated Urinary Tract 
Infection [3-10]. It is official in United States Pharmacopoeia (USP) 
2015 and British Pharmacopoeia (BP) 2015 [11].  
Both the pharmacopoeia describes HPLC method of analysis for 
Cefixime trihydrate. HPLC method is also official in Indian 
Pharmacopoeia 2014[12] and Japan Pharmacopoeia 2014[13]. 
Literature reports many analytical methods for the determination of 
CEF in single and in combination with other drug, using UV 






























Fig. 1: Chemical structures of (a) Cefixime and (b) Moxifloxacin 
 
Moxifloxacin (MFN), 1-cyclopropyl-7-[(1S,6S)-2,8-diazabicyclo 
[4.3.0] non-8-yl]-6 fluoro-8-methoxy-4-oxo-quinoline-3-carboxylic 
acid [fig.1(b)] is a synthetic fourth generation floro quinolone 
antibiotic[26]. The mechanism of action involve inhibition of an 
enzyme topoisomerase II (DNA gyrase), which is essential for 
bacterial DNA replication [27]. It is used in ocular infection 
(conjunctivitis), acute sinusitis, lower respiratory tract infections 
and urinary tract infection [28-32]. Moxifloxacin is official in BP 
2010[33]. Several analytical methods have been reported for the 
determination of MFN in formulations and biological fluids, such as 
UV spectroscopic methods [34-35], Spectro fluorometry [36], RP-
HPLC [37-41], and capillary electrophoresis [42-43]. 
The new combination of MFN and CEF is approved by the Central 
Drugs Standard Control Organization (CDSCO) India for the 
treatment of lower respiratory tract infections in adults [44].  
Simultaneous determination of these drugs is essential in each step of 
initial formulation development and screening stage of any solid dosage 
form. This combination is not official in any of the pharmacopeia and no 
official method is available for the simultaneous estimation of Cefixime 
and Moxifloxacin in the combined dosage forms.  
The objective of the current study is to develop a easy, rapid, 
accurate, reliable, reproducible, validated and economical Difference 
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Spectroscopy Method for the simultaneous determination of CEF 
and MFN in tablet dosage forms. 
MATERIALS AND METHODS 
Apparatus 
UV/Visible Spectrophotometer: SICAN-2301, Inkarp Instruments Pvt 
Ltd. 
Analytical Balance: Sartorious BSA223S-CW  
Magnetic Stirrer: REMI 1MLH, Remi Laboratories Limited. 
Chemicals and reagents 
Moxifloxacin: Gift sample from Covalent Laboratories Pvt. Ltd., 
Hyderabad. 
Cefixime: Gift sample from Neuland Laboratories Ltd., Hyderabad. 
Formulation of Moxifloxacin and Cefixime: Moxicip FC, Cipla Limited 
and Mahacef, Mankind Ltd. 
Solvent: Methanol Analytical Grade, Merck. 
Diluent: 0.1N Sodium Hydroxide, 0.1N Hydrochloric acid 
Method development and optimization 
Preparation of standard stock solution and construction of 
calibration curve 
Preparation of Moxifloxacin standard stock solution and 
plotting overlay UV spectra 
The stock solution of MFN was prepared by dissolving 50 mg of pure 
MFN in 50 ml of methanol. Appropriate aliquots of the stock solution 
were transferred into two different 25 ml volumetric flasks. The 
volume was made up with 0.1 N HC1 and 0.1 N NaOH to give a series 
of equimolar solutions of 25 ml each in 0.1 N HC1 and 0.1 N NaOH 
containing 4-20 µg/ml of MFN. The wavelength scan over a range 
400-200 nm was taken and overlay spectra was plotted (fig. 2). 
 
 
Fig. 2: Overlay UV Spectra of Moxifloxacin (4-20 μg/ml) 
 
Preparation of Cefixime standard stock solution and plotting 
overlay of UV spectra 
The stock solution of CEF was prepared by dissolving 50 mg of pure 
CEF in 50 ml of methanol. Appropriate aliquots were used as for 
MFN to prepare 25 ml series of equimolar solutions of CEF in 0.1 N 
HC1 and 0.1 N NaOH containing 10-50 µg/ml CEF. The wavelength 
scan over a range 400-200 nm were taken and overlay spectra was 
plotted (fig. 3). 
Calibration curve for moxifloxacin and cefixime trihydrate and 
their synthetic mixtures 
Similar to above, two series of equimolar solutions of mixtures of 25 
ml MFN and CEF in 0.1 N HCI and 0.1N NaOH were also prepared 
using the stock solutions. The first series contained a constant 
concentration of CEF (20 µg/ml) and a varying concentration of MFN 
(4-20 µg/ml). The second series contained a constant concentration 
of MFN (20 µg/ml) and a varying concentration of CEF (10-50 
µg/ml). The drugs were protected from light throughout the study 
and the absorbance of the solutions of pure MFN, CEF and their 
mixtures were taken between 30 and 90 min after preparation. All 
reagents used were of analytical grade. 
 
 
Fig. 3: Overlay UV spectra of cefixime (10-50 μg/ml) 
 
 Estimation of moxifloxacin and cefixime in combined tablet 
dosage form 
Twenty tablets were accurately weighed, well powdered and a 
weight of the powder equivalent to 100 mg of MFN (and 100 mg of 
CEF) was dissolved in 40 ml of methanol by thorough mixing and 
made up to volume in a 100 ml volumetric flask. The extract was 
filtered through a Whatman filter paper No. 41. The first and last 5 
ml of the filtrate was discarded. The sample solutions of 25 ml of 
each in 0.1 N HC1 and 0.1 N NaOH were prepared using 0.5 ml 
aliquots of the filtrate using a micropipette (range 100-1000 µl) so 
as to obtain equimolar solutions containing approximately 20µg/ml 
of MFN and 20µg/ml of CEF. The absorbance difference (δA) 
between the acidic solution and equimolar 0.1 N NaOH solutions of 
pure drugs and samples were measured from 230 to 400 nm on a 
SICAN-2301 UV-visible double beam auto scan spectrophotometer 
by placing the 0.1 N NaOH solutions in the reference compartment 
and the acidic solutions in the sample compartment (fig. 4). 
 
 
Fig. 4: Overlay spectra of cefixime (20 μg/ml) and Moxifloxacin 
(20μg/ml) 
 
Selection of wavelength 
The absorbance difference of the analytes at 254 and 292 nm was 
corrected for the absorbance difference, if any, of 0.1 N NaOH 
solution relative to 0.1 N HC1 at these wavelengths. The difference 
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absorption spectrum of a solution of MFN in 0.1 N HCI solutions in 
the reference cell and an equimolar solution of MFN in 0.1 N NaOH 
solutions in the sample cell compartment showed a maximum value 
of δA at 301 nm and a minimum value of δA at 283.5 nm. An 
isosbestic point (a wavelength of zero δA due to equal absorptivities 
of the two species) occurred at 292 nm (fig. 4). The difference 
absorption spectrum of solutions of CEF showed maximum values of 
δA at 297 nm and a minimum value of δA at 268 nm. The isosbestic 
points of the CEF spectrum were obtained at 254 nm (fig. 4). 
The wavelength of 254 nm was chosen for the estimation of MFN. 
For the wavelength of 254 nm, at which the δA value of the MFN 
difference spectrum was about 0.103 for a concentration of 20 
μg/ml, the absorbance value of the CEF difference spectrum was 
about 0.241 at 292 nm for a concentration of 20 μg/ml. These 
concentrations were chosen on the basis of the proportions of MFN 
and CEF in commercial formulations. The proportionality of the δA 
value and concentration of MFN was found by measuring δA of the 5 
pairs of solutions containing 4-20μg/ml of MFN at 254 nm. The 
linear regression equation calculated using the method of least 
squares was y = 0.0051x+0.0007 (1) with a correlation coefficient of 
r = 0.9994. The proportionality of δA and the concentration of CEF 
were found by measuring the δA values of solutions of CEF 
containing 10-50 μg/ml at 292 nm. The calculated linear regression 
equation was y = 0.0164x-0.0698 (2) with a correlation coefficient of 
r = 0.9994 (fig. 5 and table 1) 
Method validation 
The developed method was validated according to ICH Guidelines 
[45]. The following parameters were considered: specificity, 
linearity, limit of detection (LOD), limit of quantitation (LOQ), 
accuracy, and precision. 
Specificity 
To evaluate further the specificity of the method for samples 
containing MFN and CEF, two series each of 5 solutions (mentioned 
under standard preparation) were examined at the isosbestic 
wavelengths. The solutions of the first series gave a regression 
equation of y = 0.0053x+0.0017 (3) with a correlation coefficient of 
r= 0.9995at 254 nm, which was similar to that of Eq. (1), suggesting 
that the presence of CEF did not affect the absorptivity of MFN at 
254 nm. The δA values of the second series of solutions gave a 
regression equation of y = 0.0166x-0.0709 (4) with a correlation 
coefficient of r = 0.9993 at 292 nm. Its similarity to Eq. (2) suggests 
no interference of the absorptivity of MFN with that of CEF at 292 
nm. The identical isosbestic points of the two components in the 
standard and sample difference spectra confirmed the non-
interference of the excipients in the measurement of the absorbance 
values at these wavelengths. 
Linearity and range 
Linearity is expressed in terms of correlation co-efficient of linear 
regression analysis. The linearity response was determined by analyzing 
5 independent levels of calibration curve in the range of 4-20 μg/ml for 
Moxifloxacin and 10-50 μg/ml for Cefixime. Plot the calibration 
curve of absorbance v/s concentration and determine correlation 







Fig. 5: Linearity graph for (a) Moxifloxacin (4-20 μg/ml) and (b) 
Cefixime (10-50 μg/ml) 
 
Table 1: Data of optical characteristics 
Parameters Observed Value 
Drugs 
Moxifloxacin Cefixime 
Beer’s Law Limit (μg/ml) 10-50 µg/ml 4-20 µg/ml 
Correlation Coefficient (R2) 0.9994 0.9994 
Regression Equation (y=mx+c) y = 0.0051x+0.0007 y = 0.0164x-0.0698 
 Slope 0.0051 0.0164 
  Intercept 0.0007 -0.0698 
 
Accuracy 
Preparation of sample solution 
Twenty tablets were powdered. Powder equivalent to 400 mg of 
Moxifloxacin and 400 mg of Cefixime was weighed and transferred 
into 400 ml of the volumetric flask. Then 80 ml of methanol was 
added and solution was sonicated for 20 minutes and diluted up to 
mark with Distilled Water. The solution was filtered using Whatman 
filter paper no.41 and first few drops of filtrate were discarded. 
Known amounts of standard solutions of MFN (4.8, 6, 7.2 μg/ml) and 
CEF (12, 15, 18μg/ml for CEF) were added to pre quantified sample 
solutions of MFN (6μg/ml) and CEF (15 μg/ml) of tablet dosage 
form. Absorbances of solutions were measured at selected 
wavelengths for MFN and CEF.  
The amounts of MFN and CEF were estimated by applying obtained 
values (n = 6) to the regression equation of the calibration curve. 
The amount of MFN and CEF was calculated at each level and % 
recoveries were computed (table 2). 
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Table 2: Recovery studies 
Accuracy (Recovery studies of moxifloxacin) SD 
+ 
%RSD 




















1 6 4.8 10.89 4.89 101.88 1.20 1.19 
2 6 4.8 10.79 4.79 99.79 
3 6 4.8 10.89 4.89 101.88 
    Mean 101.18 
Moxifloxacin 
(100%) 
1 6 6 12.11 6.11 101.83 1.93 1.93 
2 6 6 12.02 6.02 100.33 
3 6 6 11.88 5.88 98.00 
    Mean 100.06 
Moxifloxacin 
(120%) 
1 6 7.2 13.11 7.11 98.75 1.18 1.18 
2 6 7.2 13.28 7.28 101.11 
3 6 7.2 13.19 7.19 99.86 
    Mean 99.91 
 
Accuracy (Recovery studies of cefixime) 



















Cefixime (80%) 1 15 12 26.87 11.87 98.92 1.89 1.89 
2 15 12 26.93 11.93 99.42 
3 15 12 27.29 12.29 102.42 
    Mean 100.25 
Cefixime 
(100%) 
1 15 15 29.87 14.87 99.13 1.21 1.21 
2 15 15 30.21 15.21 101.40 
3 15 15 29.93 14.93 99.53 
    Mean 100.02 
Cefixime 
(120%) 
1 15 18 32.89 17.89 99.39 1.00 0.99 
2 15 18 33.19 18.19 101.06 
3 15 18 33.21 18.21 101.17 




Solutions containing 8, 12, 16 μg/ml MFN and 20, 30, 40μg/ml CEF 
in triplicates were analyzed thriceon the same day. The results were 
reported in terms of relative standard deviation (%RSD) (table 3). 
Interday (Intermediate) 
Solutions containing 8, 12, 16 μg/ml MFN and 20, 30, 40 μg/ml of 
CEF in triplicates were analyzed for 3 different days. The results 
were reported in terms of relative standard deviation (%RSD) 
(table 3). 
 
Table 3: Precision studies 
Intraday analysis of formulation SD %RSD 
Drug Sampling Time Concentration (μg/ml) taken Concentration found (μg/ml) %age obtained 
 9:00 AM 8 8.07 100.85 0.13 1.54 
Moxifloxacin 1:00 AM 12 12.00 100.03 0.19 1.61 
 5:00 PM 16 16.05 100.3 0.15 0.96 
 9:00 AM 20 20.07 100.36 0.18 0.87 
Cefixime 1:00 AM 30 30.08 100.26 0.18 0.60 
 5:00 PM 40 39.81 99.52 0.48 1.22 
Interday analysis of formulation SD %RSD 
Drug Sample No. Concentration (μg/ml) taken Concentration found (μg/ml) %age obtained 
 Day 1 8 8.03 100.38 0.14 1.68 
Moxifloxacin Day 2 12 12.03 100.27 0.15 1.28 
 Day 3 16 16.05 100.34 0.21 1.29 
 Day 1 20 20.07 100.36 0.17 0.84 
Cefixime Day 2 30 30.08 100.25 0.17 0.58 
 Day 3 40 40.02 100.05 0.14 0.34 
 
Limit of detection (LOD) and limit of quantitation (LOQ) 
The LOD and LOQ of MFN and CEF by proposed methods were 
determined using calibration standards. LOD and LOQ were 
calculated as 3.3σ/S and 10σ/S respectively, where S is the slope of 
the calibration curve and σ is the standard deviation of response.  
RESULTS 
The solubility of Moxifloxacin and Cefixime was studied and distilled 
water was selected as a choice of solvent. Two drugs individually 
followed Beer-Lambert’s law over the concentration range of 10-50 
μg/ml for CEF and 4-20 μg/ml for MFN. Coefficient of correlation for 
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MFN and CEF were found to be 0.9994 and 0.9994 respectively. The 
values of correlation coefficient suggest the level of precision of 
the method. Drug content in tablet (amount present) was 
directly found from the above mentioned regression equations 
for both drugs. Standard deviations, and % RSD were calculated 
and are given in table 4. Percentage estimation in tablet dosage 
form was 101.07% and 101.06% (%RSD<2) for MFN and CEF 
respectively (table 4).  
DISCUSSION 
In the present study, the difference absorption spectra of MFN in 0.1 
N NaOH vs. 0.1 N HCl showed zero crossing point at 292, 328 and 
377 nm. The wavelength of 292 nm was chosen for measuring the 
absorbance of CEF, since the (δA) values of the CEF difference 
spectra at this point were more optimal and linear for accurate 
measurement of different concentrations of CEF.  
Similarly, the difference absorption spectra of CEF in 0.1 N NaOH vs. 
0.1 N HCl showed zero crossing point at 254 and 320 nm, but the 
absorbance of MFN was measured at the wavelength of 254 nm due 
to more linear (δA) values at this wavelength. 
The method was validated according to International Conference on 
Harmonization guidelines for validation of analytical procedures. Linear 
regression equations (intercepts and slopes) for MFN and CEF were 
established. The values of slope, intercept and correlation coefficient 
values are given in table 1. LOD for TAZ and CEF were found to be 0.92 
μg/ml and 0.98 μg/ml, respectively. LOQ for TAZ and CEF were found to 
be 2.79 μg/ml and 2.97 μg/ml, respectively. To study the validation 
parameters accuracy, reproducibility, reliability and interference, 
recovery experiment was carried out by standard addition. The recovery 
of added standard was calculated at different concentration levels. From 
the total amount of drug found, the percentage recovery was calculated 
which was between 98-102 % (RSD<2.0). 
 
Table 4: Analysis of tablet formulation 
Brand Drug Labeled Claim (mg/tab) Amount Found (mg/tab) %Purity SD %RSD 
Mahacef (Mankind) Moxifloxacin 400 404.29 101.07 1.35 0.34 
Cefixime 400 404.23 101.06 0.74 0.18 
Moxicip (Cipla) Moxifloxacin 400 404.14 101.04 0.90 0.22 
Cefixime 400 403.92 100.98 0.68 0.17 
 
CONCLUSION 
The proposed method is simple, precise, and accurate for the 
simultaneous determination of Moxifloxacin and Cefixime in 
combined tablet dosage forms and this method may be successfully 
applied in quality control laboratories for their determination in 
combined dosage form. 
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